- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00177164
Risperdal Consta for Bipolar Disorder
A Random Assignment,Parallel Group, Open Label Comparison of Clinical Outcomes and Resource Utilization Among Bipolar Disorder Patients Receiving Either Long Acting Injectable Risperidone Microspheres (Risperdal Consta® ) or Other Second Generation Oral Antipsychotic Agents: A 15 Month Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVE:
To evaluate if a long acting injectable form of risperidone offers clinical advantages over comparison oral second generation antipsychotic agents following titration and stabilization in bipolar subjects. In keeping with current practice, it is expected the vast majority of patients will also be receiving either lithium or valproate or other anticonvulsants. Following the stabilization phase several clinical events will be evaluated for up to 15 months in the two treatment groups to examine differences in clinical outcomes between those receiving the injectable versus oral medicines.
RESEARCH PLAN:
We intend to recruit 50 consenting adult subjects with DSM-IV TR diagnoses of bipolar disorder who are about to initiate or to switch their antipsychotic agent. Patients will be titrated and cross-tapered during a 3 month titration and stabilization phase. Those who transition successfully and show some improvement will be followed for an additional 12 months. Clinical outcomes such as study drop out, adverse events, worsening of symptoms, crisis interventions, need for additional medication, hospitalizations etc. will be evaluated from months 3 to 15. The numbers of clinical events (pooled) will be used to evaluate if the long acting injectable form of risperidone has an advantage over the oral second generation antipsychotic agents in terms of treatment continuity and clinical stability.
METHODS:
An open design, but treatment to either the long acting risperidone or to the oral second generation antipsychotic agents is randomly assigned. A board independent of the day-to-day clinical events will code the primary clinical outcomes of interest without knowledge of treatment assignment. The board will be provided clinical summaries of these events without revealing the treatment assignment.
SIGNIFICANCE:
The use of a long acting injectable second generation antipsychotic agent may offer advantages of treatment continuity and adherence in bipolar patients permitting improved clinical stability and improved psychosocial and functional outcomes. Such stability is difficult to achieve in the face of frequent treatment discontinuations seen with oral agents. The improved tolerability of the second generation antipsychotic agents may change the perception of long acting injections. For instance, these agents are likely to be more acceptable to patients, families and clinicians and therefore likely be used much sooner in the treatment algorithms of bipolar patients than in the past. This study will provide a treatment effect size to statistically power future comparisons of long-acting injectable vs. oral antipsychotic agents in persons with bipolar disorder
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Bridgeville, Pennsylvania, United States, 15017-1599
- Mayview State Hospital
-
Dubois, Pennsylvania, United States, 15801
- DuBois Regional Medical Center
-
McKeesport, Pennsylvania, United States, 15132
- Mon-Yough Community Services, Inc.
-
Pittsburgh, Pennsylvania, United States, 15213-2593
- Western Psychiatric Institute and Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- DSM-IV - TR diagnoses of bipolar disorder (I or II or NOS).
- Age 18 to 70 years
- Men or women
- Any Ethnicity
- Currently receiving or willing to receive treatment at sites associated with the Western Psychiatric Institute and Clinic -University of Pittsburgh Medical Center (inpatient or ambulatory) or Mon Yough Community Services, Inc. or at Mayview State Hospital, Bridgeville, PA (inpatient)
- Able to provide competent and sign an informed consent document
- It is clinically appropriate in the eligible individual to consider antipsychotic treatment for at least 15 months (clinician and investigator determined)
- It is clinically appropriate to switch antipsychotic treatment to one of the second generation antipsychotic agents being evaluated in this study.
- There is no known contraindication for the use of either risperidone or for more than two of the antipsychotic agents being considered in the study (Investigator determined)
- At entry (at the screening visit, and just prior to randomization) Y-MRS (Young-Mania rating scale, Young et al., 1978) total score > 15 in bipolar disorder patients entering in a manic or mixed or hypomanic or NOS episode.
- Either life-time or current comorbid substance abuse or dependence is permitted (unless the Investigator and referring physician opines the substance abuse is likely to significantly interfere with either the diagnosis of the Axis I condition or to compromise patients safety due to withdrawal issues (Investigator determined).
- Screening physical and laboratory/EKG procedures are within acceptable limits
Exclusion Criteria:
- Actively suicidal or dangerous to others (Investigator opines that it is inappropriate to involve the potential subject in the study)
- Pregnant or lactating women
- Women in the reproductive age group who are not using any acceptable contraception (abstinence is not acceptable) or intend to become pregnant during the trial
- Subjects who are likely to face incarceration during the study duration (and for those already in the study, the continued participation of such subjects will be evaluated on a case-by-case basis)
- Patients currently receiving clozapine (or within six weeks prior to randomization) are ineligible for the study
- Subjects currently receiving a depot neuroleptic injectable agent, or within 2 injection cycles of receiving the injection prior to randomization.
- Allergy or serious side effects (for instance - neuroleptic malignant syndrome) to either risperidone or to more than two of the other second-generation antipsychotic agents that have been approved for use in the U.S.A. (olanzapine, quetiapine, ziprasidone, aripiprazole-per investigator and referring clinician).
- Treatment resistance to either risperidone, or to more than two of the other antipsychotic agents in this trial (olanzapine, quetiapine, ziprasidone, aripiprazole).
- This is the first episode of mania, mixed or hypomania for patients.
- Current (or within one month prior to randomization) participation in an investigational drug/device study.
- Currently participating in another study that would confound the present study objectives (per investigator)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Oral Risperidone followed by Long acting Risperidone injections (Consta)
|
Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder
Other Names:
|
Active Comparator: 2
Oral second generation antipsychotic agents other than clozapine or risperidone (olanzapine, quetiapine, ziprasidone, aripiprazole)
|
Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive Either Risperidal Consta or One of the 4 Marketed 2nd Generation Antipsychotic Agents.
Time Frame: Upto 15 months
|
Upto 15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BMI
Time Frame: baseline to end of 15 months
|
BMI at baseline and at end of 15 months for Risperidone LAI and oral AAP groups
|
baseline to end of 15 months
|
Number of Participants With Treatment - Emergent Hyperglycemia
Time Frame: from baseline to end of 15 months
|
Number of participants with hyperglycemia based on safety labs
|
from baseline to end of 15 months
|
Number of Participants With Treatment Emergent Hyperlipidemia
Time Frame: from baseline to end of 15 months
|
Number of participants with Hyperlipidemia as determined by safety labs
|
from baseline to end of 15 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Bipolar and Related Disorders
- Disease
- Bipolar Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Dopamine Agonists
- Dopamine Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Olanzapine
- Aripiprazole
- Quetiapine Fumarate
- Risperidone
- Ziprasidone
- Antipsychotic Agents
Other Study ID Numbers
- RIS-PSY-405
- Univ. Pittsburgh IRB #0403091
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar I Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...H. Lundbeck A/SCompletedBipolar I DisorderUnited States, Taiwan, Romania, Korea, Republic of, Japan, Poland, Canada
-
Professor Saad ShakirMerck Sharp & Dohme LLCCompletedBipolar I DisorderUnited Kingdom
-
Solvay PharmaceuticalsWyeth is now a wholly owned subsidiary of Pfizer; H. Lundbeck A/SCompleted
-
University of Sao PauloCompleted
-
University of Sao PauloUnknown
-
Merck Sharp & Dohme LLCRecruitingBipolar I DisorderUnited States
-
Roxane LaboratoriesCompletedBipolar I DisorderUnited States
-
Eli Lilly and CompanyCompletedBipolar I DisorderUnited States
Clinical Trials on Injectable Risperidone (Consta) or oral antipsychotic
-
University of California, Los AngelesNational Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLCCompletedSchizophreniaUnited States
-
Northwestern UniversityOrtho-McNeil Janssen Scientific Affairs, LLCCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Northwell HealthNational Alliance for Research on Schizophrenia and Depression; The Zucker...TerminatedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychotic Disorder Not Otherwise SpecifiedUnited States
-
Zogenix, Inc.CompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Janssen, LPCompleted
-
Janssen Cilag N.V./S.A.Completed
-
Dartmouth-Hitchcock Medical CenterJanssen, LPCompletedPsychotic Disorders | Schizophrenia | Substance Abuse | Alcohol AbuseUnited States
-
Janssen-Cilag International NVCompletedSchizophreniaFrance, Germany, Spain, South Africa, Turkey, Greece, Czech Republic, Russian Federation
-
Duke UniversityJanssen, LPTerminatedSchizophreniaUnited States
-
University of California, Los AngelesNational Institute of Mental Health (NIMH); Janssen Scientific Affairs, LLCCompletedSchizophreniaUnited States